|
 |
| home > ebr > spring 2003 > absolute or limited product protection for biotech inventions |
|
|
 PUBLICATIONS |
European BioPharmaceutical Review
|
In the first part of this article, which appeared in the Winter 2002 issue of EBR, Dr Uta Köster investigated the pros and cons of absolute product protection against the background of the ongoing debate on the implementation of EC Directive 98/44 on the protection of biotechnological inventions (BIO-DIR) in Germany. Possible repercussions on pharmaceutical and biological R&D, as well as transferability to gene patents, were discussed with regard to relevant case law and the principles of patent law.
In Part II, a comparative analysis of the respective national laws and regulations within the EC and the US is followed by a critique of the different legal circumstances of enforcement/infringement, as related to absolute product protection versus protection limited to functions. A focus on the current granting practice of the EPO for biotechnology patents and medical applications concludes Part II.
|
Read full article >>
|
|
 |
|
| Rate this article |
You must be a member of the site to make a vote. |
|
Average rating: |
0 |
| | | | | |
|
|
 |
Industry Events |
 |
Inaugural Conference on Pre-Filled Syringes
21-22 January 2009, Crowne Plaza Hotel - St James, London, UK
SMi present their Inaugural Conference on Pre-Filled Syringes 21st and 22nd January 2009 at the Crowne Plaza Hotel - St James, London, UK
More info >> |
|
 |
News and Press Releases |
 |
BASi Opens New Office in Europe
12th November 2008
More info >> |
|
|
